Seurat Therapeutics, Inc.

CHICAGO, IL · Founded 2016 · CIK 0001732115 · Biotech · Private

Intranasal insulin-like growth factor (IGF) therapeutic for migraine treatment

seurat-therapeutics.com →
Grants
$510K
1 award
Sector median: 1
Raised
$773K
1 Form D · Feb 2018
104 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$773,487
Federal grantDepartment of Health and Human Services · Phase I · Development of Nasal IGF-1 as a Migraine Therapeutic$509,720
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1248SignalRx Pharmaceuticals Inc.—$250K
1249Tooth Bank, LLC—$200K
1250EnLiven Therapeutics—$140M
1251Seurat Therapeutics, Inc.—$773K
1252Escape Bio—$124M
1253B-TECH CONSULTING, LTD——
1254MIND BIOSCIENCES LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • Richard KraigDirector · Executive Officer
  • Sharon LewExecutive Officer
  • Martin SandersDirector · Executive Officer
  • Yuan ZhangDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.